Specialty Injectable Generics Market to Surpass US$ 75.7 Billion by 2026

Global Specialty Injectable Generics Market, by Product Type (Drugs and Biologics), by Application (Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Diseases, Auto-immune Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 31,300 million in 2017, and is projected to exhibit a CAGR of 10.4 % over the forecast period (2018 – 2026).

Increasing research and development by market players to augment the market growth Key players in the market are focused on research and development in order to develop novel products and enhance their product portfolio. For Instance, in February 2018 Oncobiologics in collaboration with Ligand Pharmaceuticals initiated a phase III trial for ONS-1045 monoclonal antibody for the treatment of colorectal cancer and lung cancer. Moreover, increasing prevalence of cancer, rheumatoid arthritis, and other chronic diseases is expected to boost the market growth. According to the Rheumatoid Arthritis Support Network, October 2018, around 1.3 million people in the U.S. and around 1 % the world population is diagnosed with rheumatoid arthritis.

Browse 34 Market Data Tables and 36 Figures spread through 238 Pages and in-depth TOC on ‘Specialty Injectable Generics Market’- Global Forecast to 2026, by Product Type (Drugs and Biologics), by Application (Oncology, Cardiovascular Diseases, Central Nervous System Diseases, Infectious Diseases, Auto-immune Disorders, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in the specialty injectable generics market, click the link below:

https://www.coherentmarketinsights.com/market-insight/specialty-injectable-generics-market-1877

Key players in the market are focused on adopting strategies such as mergers and acquisitions to enhance their product portfolio. For instance, in 2016, Teva Pharmaceutical Industries Ltd. acquired Allergan’s generics business under the name Actavis Generics. This strategic acquisition would strengthen Teva Pharmaceutical Industries’ product portfolio and expand its research & development capabilities.

Key Takeaways of the Specialty Injectable Generics Market:

• The global specialty injectable generics market is expected to exhibit a CAGR of 10.4 % over the forecast period, owing to increasing prevalence of cancer, rheumatoid arthritis, central nervous system (CNS)-associated disorders, and other diseases. For instance, according to the Alzheimer Association Report 2017, around 13.8 million people were diagnosed with Alzheimer’s dementia in the U.S.
• Among product type, the biologics segment held a dominant position in the specialty injectable generics market in 2018. This is owing to increasing investment in this segment and high number of companies that are focused on developing biosimilar version of the branded biologics injectable.
• Among application type, oncology segment held a dominant position in the specialty injectable generics market in 2018. This is owing to increasing research and development activities in oncology.
• Among distribution channel, the hospital pharmacies segment held a dominant position in the specialty injectable generics market in 2018, owing to the majority of cases related to cancer, cardiovascular diseases, and other diseases being registered in hospitals
• Key players operating in the global specialty injectable generics market include, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Baxter International Inc., Mylan N.V., Fresenius SE & Co. KGaA, Endo International Plc., Hikma Pharmaceuticals PLC, Lupin Ltd., Sagent Pharmaceuticals, Inc., Cipla Limited, Sun Pharmaceutical Industries Limited, and Dr. Reddy's Laboratories